European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH

Eli Lilly and Company (NYSE: LLY) reports that a Phase III study, published online by European Urology, showed both Cialis (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia (BPH). Cialis improved erectile dysfunction (ED) in those men who had both signs and symptoms of BPH and ED. The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin. This is the first international, placebo-controlled study evaluating Cialis in parallel with tamsulosin (as an active control) for signs and symptoms of BPH in the same population.

Cialis for daily use is approved to treat ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions (ED+BPH).

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
• Home Depot expands executive roles, grants $500K in restricted stock
• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris